血管扩张剂治疗急性心力衰竭的临床疗效以及对患者BNP水平的影响

Clinical Efficacy of Vasodilator in Acute Heart Failure and Its Effect on BNP Level

目的探讨血管扩张剂治疗急性心力衰竭的临床疗效以及对患者BNP水平的影响。方法对急性心力衰竭患者分别采用乌拉地尔(乌拉地尔组)、硝酸甘油(硝酸甘油组)和硝普钠(硝普钠组)治疗,并观察其疗效,并于治疗前后检测患者血浆BNP含量。结果三组疗效差异无统计学意义(P>0.05),硝酸甘油组和硝普钠组低血压、心率加快和氰化物中毒反应的发生率明显高于乌拉地尔组(P<0.05或P<0.01)。患者治疗前血浆BNP含量明显高于诊断界值,治疗后明显降低(P<0.01),且治疗后乌拉地尔组与其他组差异有统计学意义(P<0.05)。结论血管扩张剂治疗急性心力衰竭的临床疗效显著,其中乌拉地尔在治疗过程中副反应少,较其他血管扩张剂更为安全有效。

Objective To investigate the clinical efficacy of vasodilator in the treatment of acute heart failure（AHF） as well as its effect on BNP level. Methods AHF patients were treated with urapidil（urapidil group）,nitroglycerin（nitroglycerin group ） and sodium nitroprusside （SNP group）and their clinical efffcacy was observed,the plasma BNP level of patients was detected before and after treatment. Results The clinical efficacy of the three groups showed no significant difference （P 〉 0.05 ）. The incidence of low blood pressure, accelerated heart rate and cyanide-poisoning reaction in the nitroglycerin and SNP groups ,was significantly higher than that of urapidil group（P〈0.05 or P〈 0.01 ）. Plasma BNP level of patients before treatment was significantly higher than the critical value of diagnosis and significantly lower after treatment （P〈 0.01 ）, with a significant difference between urapidil group and other groups（P 〈 0.05 ）. Conclusion There is a significant clinical efficacy of vasodilator in the treatment of acute heart failure, the side effects of urapidil are fewer than those of other vasodilators,and therefore,it is more safe and effective.